The Carlat Psychiatry Podcast
A New Form of Lithium
Jan 8, 2024
Stephan Jackman, developer of a new formulation of lithium, discusses the use of lithium in different populations, potential benefits in reducing dementia and suicide rates, lifestyle factors impacting lithium levels, and a new formulation called LiPerSAL aiming to improve treatment with minimized side effects.
16:49
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Lithium is a first-line treatment for bipolar disorder that has fewer side effects and higher patient adherence compared to atypical antipsychotics.
- A new formulation of lithium, called LiPerSAL, has been developed to enhance its safety and effectiveness, potentially reducing physical side effects and being applicable to various mental health conditions.
Deep dives
Lithium's effectiveness in treating bipolar disorder
Lithium has become a first-line treatment for the early stages of bipolar disorder as it can help patients stay well, function better, and have a longer lifespan. Despite not having the same brand recognition as atypical antipsychotics in treating bipolar depression, lithium tends to have fewer side effects and higher patient adherence. Extended-release lithium is better tolerated than instant release, particularly regarding tremors. However, long-term lithium use does double the risk of developing Stage 3 renal failure, so close monitoring and consultation with a renal specialist are crucial.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
